NMC warned against ‘performative change’ amid new criticism | Nursing Times
Learn how nurse campaign groups have reacted to the Professional Standards Authority’s damning performance review of the nursing regulator.
Related Articles
Assisted dying bill voted through the House of Commons | Nursing Times
The Terminally Ill Adults (End of Life) Bill has passed the House of Commons and will now progress to the House of Lords. Read more.
Assisted dying bill voted through the House of Commons | Nursing Times
The Terminally Ill Adults (End of Life) Bill has passed the House of Commons and will now progress to the House of Lords. Read more.
Oliver McGowan: new training guidelines launched | Nursing Times
Read about a new code of practice to help employers deliver the Oliver McGowan learning disability and autism training.
Two Leeds maternity units rated ‘inadequate’ amid safety concerns | Nursing Times
Read about why maternity services at Leeds Teaching Hospitals NHS Trust have been downgraded from good to inadequate.
Two Leeds maternity units rated ‘inadequate’ amid safety concerns | Nursing Times
Read about why maternity services at Leeds Teaching Hospitals NHS Trust have been downgraded from good to inadequate.
What I Would Tell the Woman I Was Before Breast Cancer
After being diagnosed with breast cancer at 39, I learned to advocate for myself, transforming fear into fierce resolve and purpose through every step.
NMC warned against ‘performative change’ amid new criticism | Nursing Times
Learn how nurse campaign groups have reacted to the Professional Standards Authority’s damning performance review of the nursing regulator.
‘Why is substance use training so limited for nurses?’ | Nursing Times
Student editor Rebecca Kenderdine on the current training available for treating patients with dual diagnosis.
‘To attract and retain the nurses of the future, we need to show the full picture’ | Nursing Times
Jaime Day on why nursing needs to show the full picture of the profession and not just the adrenaline-fuelled action of CPR and A&E, in…
FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis
The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.